- Class period: December 17, 2025 to July 26, 2026.
- Lead plaintiff deadline: September 28, 2026.
- Lawsuit filed by Schall, Brown & Schwartz LLP.
- Allegation: Capricor changed the statistical analysis plan for Deramiocel without FDA agreement.
- Allegation: Capricor faced significant risk the FDA would not approve the Deramiocel BLA.
- Capricor trades on NASDAQ under ticker CAPR.
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card